Medtronic, Inc. (NYSE: MDT) a annoncé aujourd'hui que l'essai clinique de grande envergure RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results